Monday, 25 Mar 2019

You are here

Two Lupus Studies

In this session we were given new data on ustekinumab for SLE (abstract 6L). Ustekinumab is an IL12/23 agent already approved for use in psoriasis, psoriatic arthritis and Cohn’s disease. This abstract presented results from a Phase II trial in active SLE. The trial enrolled 102 active SLE patients who were randomised to ustekimumab or placebo (3:2 ratio) and followed for 24 weeks with the SRI-4 being used as the primary end-point.  At week 24, the primary end-point was achieved in 60% of ustekinumab and 31% of placebo patients (p=0.0046). The risk of a flare was also lower in the ustekinumab treated group (p=0.0078). Skin and joint disease activity improved more in the ustekinumab group in those with activity in these organs at baseline. There were no significant imbalances in serious adverse events between the groups. A Phase III trial is now in development. 

Of interest, an abstract (2609) on Tuesday reported a data driven approach to literature mining to aid in identifying new potential targets for SLE therapy and using an objective scoring system. This approach had previously assessed ustekinumab as a potential target of interest in SLE. The results of this Phase II trial are also therefore nice proof of concept data to support this approach. Abstract 2609 reporting the literature mining exercise has also identified an additional 25 potential drugs for repurposing in SLE.

Hopefully there will be more to come both from this agent and the others from this pipeline to help address the significant unmet need in SLE.  

Add new comment

More Like This

Autoimmune Disease Clustering at ENDO 2019

A twin registry database study was presented at the Endocrine Society's annual meeting (ENDO 2019) in New Orleans, showed that that having autoimmune disease significantly increases the risk of other autoimmune disorders and that autoimmune clustering was highest in Addison's disease and vitiligo. 

Resistant Hypertension Common in SLE

Rates of resistant hypertension were doubled among patients with systemic lupus erythematosus (SLE), significantly increasing their mortality risks, a retrospective single-center study found.

Among patients with SLE, the prevalence of resistant hypertension was 10.2% compared with 5.3% among controls (OR 2.02, 95% CI 1.60-2.55, P<0.0001), according to Cecilia P. Chung, MD, and colleagues from Vanderbilt University in Nashville.

Improved Mortality Trends in Lupus Nephritis

The mortality rate from end- stage renal disease (ESRD) in lupus nephritis (LN) patients has significantly decreased in the last decade.

Cyclosporin and IVIG Effective in Kawasaki's Disease

A Lancet study has shown that adding cyclosporin to intravenous immunoglobulin (IVIG) Kawasaki disease patients, who were predicted to be resistant to IVIG, was both safe and effective in averting severe coronary artery outcomes.

Brazilian Guidelines for Systemic Autoimmune Myopathies

The Myopathy Committee of the Brazilian Society of Rheumatology (BSR) has put forward recommendations for the management of patients with systemic autoimmune myopathies (SAM).

The challenge has been that there is a paucity of effective controlled clinical trials, and hence, glucocorticoids (GC) have played a first-line and prominent role in the treatment of SAM.